Bridgewater Associates LP Has $12.35 Million Position in Chemed Co. (NYSE:CHE)

Bridgewater Associates LP lowered its position in Chemed Co. (NYSE:CHE) by 28.7% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 20,556 shares of the company’s stock after selling 8,266 shares during the quarter. Bridgewater Associates LP’s holdings in Chemed were worth $12,354,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of the stock. GAMMA Investing LLC raised its position in shares of Chemed by 34.4% in the second quarter. GAMMA Investing LLC now owns 86 shares of the company’s stock valued at $47,000 after purchasing an additional 22 shares during the period. Ballentine Partners LLC raised its position in shares of Chemed by 4.1% in the third quarter. Ballentine Partners LLC now owns 655 shares of the company’s stock valued at $394,000 after purchasing an additional 26 shares during the period. Everpar Advisors LLC raised its position in shares of Chemed by 4.9% in the second quarter. Everpar Advisors LLC now owns 580 shares of the company’s stock valued at $315,000 after purchasing an additional 27 shares during the period. Creative Planning raised its position in shares of Chemed by 2.8% in the second quarter. Creative Planning now owns 1,228 shares of the company’s stock valued at $667,000 after purchasing an additional 34 shares during the period. Finally, First Heartland Consultants Inc. increased its position in Chemed by 7.2% during the third quarter. First Heartland Consultants Inc. now owns 508 shares of the company’s stock worth $305,000 after acquiring an additional 34 shares during the period. 95.85% of the stock is owned by institutional investors.

Insider Buying and Selling at Chemed

In other Chemed news, CEO Kevin J. Mcnamara sold 2,000 shares of the firm’s stock in a transaction dated Thursday, September 26th. The shares were sold at an average price of $598.81, for a total value of $1,197,620.00. Following the transaction, the chief executive officer now directly owns 103,735 shares of the company’s stock, valued at $62,117,555.35. This trade represents a 1.89 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Nicholas Michael Westfall sold 1,713 shares of the firm’s stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $569.35, for a total transaction of $975,296.55. Following the completion of the transaction, the executive vice president now directly owns 6,109 shares in the company, valued at approximately $3,478,159.15. This represents a 21.90 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 6,113 shares of company stock valued at $3,557,445 in the last ninety days. 3.32% of the stock is currently owned by company insiders.

Chemed Stock Performance

NYSE:CHE opened at $571.31 on Friday. Chemed Co. has a 52 week low of $523.33 and a 52 week high of $654.62. The firm has a market cap of $8.60 billion, a price-to-earnings ratio of 28.87, a P/E/G ratio of 2.43 and a beta of 0.46. The firm’s 50-day simple moving average is $578.74 and its 200 day simple moving average is $565.02.

Chemed (NYSE:CHE) last released its earnings results on Tuesday, October 29th. The company reported $5.64 EPS for the quarter, missing the consensus estimate of $5.76 by ($0.12). Chemed had a net margin of 12.69% and a return on equity of 27.86%. The firm had revenue of $606.18 million during the quarter, compared to the consensus estimate of $612.22 million. During the same period in the prior year, the business earned $5.32 earnings per share. Chemed’s quarterly revenue was up 7.4% compared to the same quarter last year. Sell-side analysts anticipate that Chemed Co. will post 21.43 EPS for the current year.

Chemed Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, December 6th. Shareholders of record on Monday, November 18th will be issued a $0.50 dividend. This represents a $2.00 annualized dividend and a yield of 0.35%. The ex-dividend date of this dividend is Monday, November 18th. Chemed’s dividend payout ratio is currently 10.11%.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the stock. StockNews.com lowered shares of Chemed from a “buy” rating to a “hold” rating in a research report on Friday, November 22nd. Royal Bank of Canada lowered their price target on shares of Chemed from $697.00 to $633.00 and set an “outperform” rating on the stock in a research report on Tuesday, November 5th.

Chemed Profile

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.